SG10201507865QA - Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor - Google Patents
Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitorInfo
- Publication number
- SG10201507865QA SG10201507865QA SG10201507865QA SG10201507865QA SG10201507865QA SG 10201507865Q A SG10201507865Q A SG 10201507865QA SG 10201507865Q A SG10201507865Q A SG 10201507865QA SG 10201507865Q A SG10201507865Q A SG 10201507865QA SG 10201507865Q A SG10201507865Q A SG 10201507865QA
- Authority
- SG
- Singapore
- Prior art keywords
- fused bicyclic
- fak inhibitor
- diaminopyrimidine derivative
- dual alk
- alk
- Prior art date
Links
- 229940122531 Anaplastic lymphoma kinase inhibitor Drugs 0.000 title 1
- 229940124783 FAK inhibitor Drugs 0.000 title 1
- -1 bicyclic 2,4-diaminopyrimidine derivative Chemical class 0.000 title 1
- 230000009977 dual effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261607305P | 2012-03-06 | 2012-03-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201507865QA true SG10201507865QA (en) | 2015-10-29 |
Family
ID=47892060
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201507865QA SG10201507865QA (en) | 2012-03-06 | 2013-03-06 | Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor |
| SG11201405371PA SG11201405371PA (en) | 2012-03-06 | 2013-03-06 | Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201405371PA SG11201405371PA (en) | 2012-03-06 | 2013-03-06 | Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor |
Country Status (28)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA115052C2 (uk) * | 2012-03-06 | 2017-09-11 | Сефалон, Інк. | Конденсоване біциклічне 2,4-діамінопіримідинове похідне як подвійний alk- i fak-інгібітор |
| JP6783224B2 (ja) | 2014-04-04 | 2020-11-11 | デル マー ファーマシューティカルズ | 肺の非小細胞癌腫及び卵巣癌を処置するためのジアンヒドロガラクチトール及びその類縁体又は誘導体の使用 |
| US10259794B2 (en) * | 2014-12-23 | 2019-04-16 | Cephalon, Inc. | Methods for preparing fused bicyclic 2, 4-diaminopyrimidine derivatives |
| JP2021534094A (ja) | 2018-08-07 | 2021-12-09 | イン3バイオ・リミテッドIn3Bio Ltd. | 未分化リンパ腫キナーゼ阻害剤と組み合わせてｅｇｆ／ｅｇｆｒ経路を抑制するための方法および組成物 |
| WO2024178339A2 (en) * | 2023-02-23 | 2024-08-29 | The Regents Of The University Of Michigan | Methods for treating neuroblastoma with a dual anaplastic lymphoma kinase and focal adhesion kinase inhibitor |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005009389A2 (en) | 2003-07-23 | 2005-02-03 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
| BR122019017579B8 (pt) | 2003-08-15 | 2021-07-27 | Novartis Ag | 2,4-pirimidinadiaminas, seus usos, combinação e composição farmacêutica |
| ES2424642T3 (es) * | 2004-02-14 | 2013-10-07 | Irm Llc | Compuestos y composiciones como inhibidores de la proteína quinasa |
| WO2005097765A1 (en) | 2004-03-31 | 2005-10-20 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
| JP2009528295A (ja) * | 2006-02-24 | 2009-08-06 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ｊａｋ経路の阻害のための組成物および方法 |
| CL2007003049A1 (es) | 2006-10-23 | 2008-05-16 | Cephalon Inc Pharmacopeia Drug | Compuestos derivados de 2,4-diaminopirimidina; composicion farmaceutica, utiles para tratar trastornos proliferativos. |
| MY148427A (en) * | 2006-12-08 | 2013-04-30 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| KR101132880B1 (ko) * | 2007-04-18 | 2012-06-28 | 화이자 프로덕츠 인크. | 비정상적인 세포 성장의 치료를 위한 술포닐 아미드 유도체 |
| DK2441753T3 (en) * | 2009-06-10 | 2016-05-30 | Chugai Pharmaceutical Co Ltd | Tetracyclic COMPOUND |
| UA115052C2 (uk) * | 2012-03-06 | 2017-09-11 | Сефалон, Інк. | Конденсоване біциклічне 2,4-діамінопіримідинове похідне як подвійний alk- i fak-інгібітор |
| KR101446742B1 (ko) * | 2012-08-10 | 2014-10-01 | 한국화학연구원 | Ｎ2,ｎ4-비스(4-(피페라진-1-일)페닐)피리미딘-2,4-디아민 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
| US10259794B2 (en) * | 2014-12-23 | 2019-04-16 | Cephalon, Inc. | Methods for preparing fused bicyclic 2, 4-diaminopyrimidine derivatives |
-
2013
- 2013-03-06 UA UAA201410832A patent/UA115052C2/uk unknown
- 2013-03-06 RS RS20160238A patent/RS54689B1/en unknown
- 2013-03-06 MX MX2014010613A patent/MX347772B/es active IP Right Grant
- 2013-03-06 HR HRP20160387TT patent/HRP20160387T1/hr unknown
- 2013-03-06 HU HUE13710258A patent/HUE027976T2/en unknown
- 2013-03-06 AU AU2013229995A patent/AU2013229995B2/en active Active
- 2013-03-06 MY MYPI2014002428A patent/MY177290A/en unknown
- 2013-03-06 CA CA2865420A patent/CA2865420C/en active Active
- 2013-03-06 SG SG10201507865QA patent/SG10201507865QA/en unknown
- 2013-03-06 PL PL13710258T patent/PL2822939T3/pl unknown
- 2013-03-06 MX MX2017006206A patent/MX372740B/es unknown
- 2013-03-06 KR KR1020147027590A patent/KR102068374B1/ko active Active
- 2013-03-06 ME MEP-2016-68A patent/ME02460B/me unknown
- 2013-03-06 EP EP13710258.8A patent/EP2822939B1/en active Active
- 2013-03-06 EP EP15202516.9A patent/EP3056494B1/en active Active
- 2013-03-06 SI SI201330151T patent/SI2822939T1/sl unknown
- 2013-03-06 CN CN201610591742.5A patent/CN106166155B/zh active Active
- 2013-03-06 EA EA201691574A patent/EA033124B1/ru not_active IP Right Cessation
- 2013-03-06 JP JP2014561069A patent/JP6016953B2/ja not_active Expired - Fee Related
- 2013-03-06 NZ NZ630251A patent/NZ630251A/en unknown
- 2013-03-06 WO PCT/US2013/029304 patent/WO2013134353A1/en active Application Filing
- 2013-03-06 ES ES15202516.9T patent/ES2681487T3/es active Active
- 2013-03-06 SG SG11201405371PA patent/SG11201405371PA/en unknown
- 2013-03-06 CN CN201380012764.6A patent/CN104159894B/zh active Active
- 2013-03-06 ES ES13710258T patent/ES2570976T3/es active Active
- 2013-03-06 EA EA201491641A patent/EA025859B1/ru not_active IP Right Cessation
- 2013-03-06 DK DK13710258.8T patent/DK2822939T3/en active
-
2014
- 2014-08-21 ZA ZA2014/06147A patent/ZA201406147B/en unknown
- 2014-08-21 IL IL234239A patent/IL234239A/en active IP Right Grant
- 2014-09-02 US US14/474,928 patent/US9132128B2/en active Active
- 2014-09-05 CL CL2014002353A patent/CL2014002353A1/es unknown
- 2014-09-05 PH PH12014501979A patent/PH12014501979B1/en unknown
-
2015
- 2015-08-12 US US14/824,750 patent/US9339502B2/en active Active
-
2016
- 2016-05-04 US US15/146,164 patent/US9623026B2/en not_active Expired - Fee Related
- 2016-05-10 CY CY20161100390T patent/CY1117565T1/el unknown
- 2016-05-10 SM SM201600134T patent/SMT201600134B/it unknown
- 2016-09-27 JP JP2016188585A patent/JP2017039741A/ja active Pending
-
2017
- 2017-03-07 US US15/451,960 patent/US10111872B2/en active Active
- 2017-05-18 IL IL252364A patent/IL252364B/en active IP Right Grant
-
2018
- 2018-10-26 US US16/172,368 patent/US10632119B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL281461A (en) | Extension joint | |
| IL252364B (en) | A fused bicyclic 2, 4-diaminopyrimidine derivative as a double alk and fak inhibitor | |
| PL2802240T3 (pl) | Złącze meblowe | |
| IL237126A (en) | Derivatives in cicadas | |
| ZA201405045B (en) | Pyrazinecarboxamide compound | |
| PL2824181T3 (pl) | Nowa fuzja fgfr3 | |
| ZA201407828B (en) | Bicyclic pyrazinone derivatives | |
| SG11201406860SA (en) | Quinazolinedione derivative | |
| SI4082524T1 (sl) | Formulacije s triazinom | |
| EP2887831A4 (en) | SHOE ARTICLES | |
| GB2505195B (en) | Joint configuration | |
| GB201218278D0 (en) | Translocating peptide | |
| AU2012905685A0 (en) | The Kangaroo Waterstorm | |
| AU4710P (en) | Fusion xTriticosecale | |
| GB201212160D0 (en) | Cyclone | |
| GB201220095D0 (en) | Structural joint | |
| GB201215277D0 (en) | Structural joint | |
| GB201203314D0 (en) | Structural joint |